PhAST Raises $3.47M Series B to Revolutionize Rapid Pathogen Diagnostics with Single-Cell Imaging Advances

PhAST is thrilled to announce a successful funding round that secured $3,470,000 to further advance our transformative diagnostic technologies.

We believe that innovative technology can fundamentally change the battle against infectious diseases, and this infusion of capital will accelerate our mission to deliver rapid, actionable insights on pathogens.

Our breakthrough approach harnesses the power of single-cell imaging, allowing us to capture immediate and comprehensive data on microorganisms—a process that traditionally takes days but can now be accomplished in mere minutes.

This milestone support not only validates our efforts but also empowers our multidisciplinary team to push the boundaries of what is possible in the field of microbiological diagnostics.

With this new funding, PhAST will expand its capabilities, refine its imaging systems, and explore additional diagnostic applications that will revolutionize the speed and accuracy of pathogen detection, identification, and antibiotic susceptibility testing.

Our goal is to provide diagnostic information right when you need it, reducing the time patients wait for crucial treatment decisions and significantly impacting global health outcomes.

By turning complex single-cell images into clear, actionable insights, we are ensuring that healthcare professionals have rapid access to the data they need to respond effectively to infectious threats.

Ultimately, this investment ushers in a new era in diagnostic technology—one that imagines the impossible and delivers innovative solutions to save lives.

At PhAST, we are not just imaging microbes; we are imaging a healthier future for everyone.